The association between biochemical control and cardiovascular risk factors in acromegaly

BMC Endocrine Disorders

Research Article

Vivien Bonert¹  John D. Carmichael¹  Adam Mamelak¹  Maureen P. Neary²  Qayyim Said²  Eunice Chang³  Dasha Cherepanov³  Michael S. Broder³ 

[1] Cedars-Sinai Medical Center, 8700 Beverly Blvd, 90048, Los Angeles, CA, USA;Novartis Pharmaceuticals Corporation, One Health Plaza, 07936-1080, East Hanover, NJ, USA;Partnership for Health Analytic Research, LLC, 280 S. Beverly Dr., Suite 404, 90212, Beverly Hills, CA, USA;

关键词: Chart review;    Patient registry;    Acromegaly;    Biochemical control;    Comorbidities;   

DOI  :  10.1186/s12902-017-0166-6

 received in 2016-11-16, accepted in 2017-03-02,  发布年份 2017

来源: Springer

【 摘 要 】

BackgroundThe study aim was to estimate the proportion of acromegaly patients with various comorbidities and to determine if biochemical control was associated with reduced proportion of cardiovascular risk factors.MethodsData were from a single-center acromegaly registry. Study patients were followed for ≥12 months after initial treatment. Study period was from first to last insulin-like growth factor-I and growth hormone tests.ResultsOf 121 patients, 55% were female. Mean age at diagnosis was 42.4 (SD: 15.0). Mean study period was 8.8 (SD: 7.2) years. Macroadenomas were observed in 93 of 106 patients (87.7%), and microadenomas in 13 (12.3%). Initial treatment was surgery in 104 patients (86%), pharmacotherapy in 16 (13.2%), and radiation therapy in 1 (0.8%). Of 120 patients, 79 (65.8%) achieved control during the study period. New onset comorbidities (reported 6 months after study start) were uncommon (<10%). Comorbidities were typically more prevalent in uncontrolled versus controlled patients—24 (58.5%) vs. 33 (41.8%) had hypertension, 17 (41.5%) vs. 20 (25.3%) had diabetes, 11 (26.8%) vs. 16 (20.3%) had sleep apnea, and 3 (7.3%) vs. 3 (3.8%) had cardiomyopathy—except for colon polyps or cancer (19.5% vs. 20.3%), left ventricular hypertrophy (9.8% vs. 11.4%), and visual defects (14.6% vs. 17.7%).ConclusionsA greater number of comorbidities were observed in biochemically uncontrolled patients with acromegaly compared to their controlled counterparts in this single-center registry. About a third of the patients remained uncontrolled after a mean of >8 years of treatment, demonstrating the difficulty of achieving control in some patients.

【 授权许可】

CC BY   
© The Author(s). 2017